OrisDX raised $4 million to support the launch of its saliva-based multiomic platform for the detection of oral cancer.
OrisDX offers a non-invasive oral rinse with 93% sensitivity and 99% specificity, according to a June 10 news release.
The company said the new funding will go toward the commercial rollout of its diagnostic platform across dental, oncology and medical channels.
At the Becker's 5th Annual Future of Dentistry Roundtable, taking place September 14-15 in Chicago, dental leaders and executives will gain insights into emerging technologies, practice growth strategies and the evolving landscape of dental care delivery, with a focus on innovation, patient experience and operational excellence. Apply for complimentary registration now.
